Univercells Technologies has completed €2m expansion of its Nivelles, Belgium site, with the goal of boosting supply chain security for biomanufacturers.
Fujifilm Corporation is to invest US$1.6bn (€1.4bn) to boost the business of its subsidiary, Fujifilm Diosynth Biotechnologies (FDB), a contract development and manufacturing organization (CDMO).
Vibalogics, which was recently acquired by Swedish company, Recipharm, says the completion of its expansion project at its facility in Germany boosts capacity and further enhances its flexibility, minimizing time to clinic for customers.
Netherlands-based gene therapy company, VectorY Therapeutics, and Wageningen University have signed a strategic collaboration agreement for the development of novel baculovirus-based AAV production technologies.
Construction of Samsung Biologics’ new facility is on track, with the CDMO saying pre-sales activities are ongoing for Plant 4, as it is known, despite the challenging business environment amid the COVID-19 pandemic.
LEXEO Therapeutics, a clinical-stage gene therapy company, is partnering with CDMO, Fujifilm Diosynth Biotechnologies (FDB), to support the development and manufacturing of its AAV-mediated gene therapies.
The operation of the 1.5 million square-foot biologics manufacturing site in Lengnau, Switzerland is part of a strategic partnership agreed with CSL Limited, announced last year, says Thermo Fisher Scientific.
Earlier this month, Rentschler Biopharma, a contract development and manufacturing organization (CDMO), announced that it had broken ground on its new production facility, adjacent to its existing site in Milford, Massachusetts, in the greater Boston...
Generate Life Sciences is establishing a GMP facility in La Jolla, California that it says will enable end-to-end manufacturing of newborn stem cell biologics, bolstering supply and safeguarding clinical research.
Gamma Biosciences has taken a controlling investment in Mirus Bio, an innovator and developer of biomimetic, cell-adaptive lipid-polymer nanocomplexes (LPNCs) for nucleic acid delivery based in Wisconsin in the US.
Contract development and manufacturing organization, Catalent, has invested in the capabilities at its clinical supply services facility in Philadelphia, in the US, to further support biotech firms developing cell and gene therapies.
Erbi Biosystems recently raised US$3.8m in a round led by Jaguar Biotech; the funds will allow the company to expand its platform of microfluidic bioprocess and bioreactor equipment, which is said to enable ultra-high cell density and continuous processing.
The Serum Institute of India will receive six 4,000L CSR bioreactors from ABEC to help it scale up manufacture of Novavax’s COVID-19 vaccine candidate.
Funding from Gamma supports the development of Univercells’ biomanufacturing platform and bioreactors, with the latter looking to expand into the fast-growing gene therapy segment.
Aiming to improve flexibility in bioprocessing, Eppendorf launches SciVario twin, a bioreactor control system enabling remote monitoring of microbial and cell culture processes.
iBio grants CC-Pharming exclusive license to commercialize rituximab in China, as well as a research license to bring its FastPharming technology to the country.
Sartorius launches a new vessel for its ambr 250 modular bioreactor system to potentially accelerate cell and gene therapy process development and scale up into cGMP single-use bioreactors and bags.
Vibalogics increases its single-use bioreactor and purification capacity with a new manufacturing line to meet demand for oncolytic virus and viral vector manufacturing services.
